logo
Merck, Daiichi pull approval application for ADC in lung cancer

Merck, Daiichi pull approval application for ADC in lung cancer

Yahoo29-05-2025
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
Merck & Co. and Daiichi Sankyo have withdrawn an approval application in the U.S. for a lung cancer drug at the center of a multibillion-dollar alliance the companies formed two years ago.
In a short statement Thursday, the companies said they've pulled a Food and Drug Administration submission for an experimental therapy known as patritumab deruxtecan. Merck and Daiichi had been seeking an 'accelerated' approval of the drug in people whose non-small cell lung cancer has a mutation in a gene called EGFR and, last September, reported that it meaningfully delayed tumor progression compared to chemotherapy in a Phase 2 trial.
However, Merck and Daiichi have also found that their drug didn't extend survival, the gold standard for a cancer drug. That finding, as well as subsequent discussions with the FDA, led the companies to withdraw their application, according to their statement.
The companies will present study results at the American Society of Oncology Meeting on Sunday.
This outcome is a 'reminder of how challenging it can be to treat these patients with EGFR-mutated non-small cell lung cancer in the second and later line settings,' said Eliav Barr, the chief medical officer of Merck Research Laboratories, in the statement.
Merck currently draws the bulk of its revenue from the cancer immunotherapy Keytruda, which in recent years became the world's top-selling drug. But Keytruda is poised to lose patent protection later this decade, and Merck has been facing increasing skepticism from analysts and investors about its plans to offset those future losses and grow. The company's share price has fallen nearly 40% over the last 12 months.
One area of research Merck has looked to is antibody-drug conjugates, a type of targeted cancer medicine seen as a potential way to replace traditional chemotherapies. The company formed a pair of alliances with China-based drugmaker Kelun Biotech in 2022 and, a year later, sprung for a collaboration with Daiichi that could potentially be worth as much as $22 billion.
In aligning with Daiichi, Merck may have been spurred on by the success AstraZeneca has had with a similar type of ADC-focused partnership. A 2019 deal between Daiichi and AstraZeneca yielded Enhertu, an ADC that's cleared for use in several cancers and is now a blockbuster medicine. Merck partnered with Daiichi a month after the Japanese company reported Phase 2 data underlying an accelerated approval application for patritumab deruxtecan.
But the companies have faced setbacks since. U.S. regulators rejected their ADC last June due to findings at a manufacturing plant. Now, after pulling their application, Merck and Daiichi are searching for a new path forward.
The companies are 'conducting further biomarker analyses' to better identify lung cancer patients who might benefit from treatment, said Ken Takeshita, Daiichi's global head of R&D, in the statement. 'We remain confident in the broad development of [our drug],' which includes trials across 15 types of cancer, he added.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness
Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness

Yahoo

time12 hours ago

  • Yahoo

Merck & Co., Inc. (MRK) Impresses Jim Cramer With Its Toughness

We recently published . Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed. Merck & Co., Inc. (NYSE:MRK)'s shares have lost 16% year-to-date as investors continue to be disappointed by the dropping revenue of its GARDASIL HPV drug in China. They are also worried about the patent expiration of the firm's mega cancer drug KEYTRUDA and wondering whether Merck & Co., Inc. (NYSE:MRK) will be able to follow up with an equally successful successor. However, the shares did gain 3% this week after Pfizer announced that its bladder cancer drug PADCEV improves survival rates when paired with KEYTRUDA. Cramer was impressed as he commented: 'Look at Merck. I mean, Saint Merck. What a tough, what a tough.' Photo by National Cancer Institute on Unsplash Here are his earlier comments about Merck & Co., Inc. (NYSE:MRK): 'Well, this GARDASIL, when is it? The Chinese are not really helping them sell, because you would have thought the Chinese would. . .and then you've got the KEYTRUDA, you know the patent cliff coming up. . .it's amazing, but they are talking about their animal division. When you're talking about your animal division you don't have enough [inaudible] to talk.' While we acknowledge the potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

Next-Generation Approaches to Hematologic Malignancies
Next-Generation Approaches to Hematologic Malignancies

Time Business News

time13 hours ago

  • Time Business News

Next-Generation Approaches to Hematologic Malignancies

Hematologic malignancies are cancer that affect blood, bone marrow, and lymphatic systems including leukemia, lymphoma and multiple myeloma. These cancers disrupt normal blood cell production and immune function. The growth of the hematologic malignancy market is inspired by increasing the prevalence of global cancer, increasing target remedies and immunotherapy, progression in clinical technologies and expanding research in individual medicine. Additionally, increasing awareness, better healthcare infrastructure, and oncology contribute to more investment market expansion in drug development. Key Growth Drivers and Opportunities Increasing the Prevalence of Global Cancer: The increasing global spread of cancer greatly enhances the growth of the market of hematologic malignancies, as blood -related cancer, such as leukemia, lymphoma and multiple myeloma, become a large part of cancer worldwide. As more individuals are affected by these conditions, there is an increasing demand for accurate diagnosis, advanced treatment options and long -term disease management solutions. In cases, this increase encourages drug companies and research institutes to invest in innovative remedies such as targeted treatment, immunotherapy and CAR-T cell therapy. Additionally, high cancer phenomena motivate governments and healthcare systems to increase screening programs and to reach oncology. Challenges Hematologic malignancies markets face several borders, including high cost of advanced treatments such as car-T cell treatment and targeted drugs, which can restrict access to patients in low- and moderate-income areas. Complex regulatory approval, long clinical testing procedures, and severe side effects or ability to resist also face significant challenges. Additionally, limited availability of specialized clinical equipment and lack of efficient health care professionals in some fields obstruct timely and accurate diagnosis, overall treatment affects results and slows down market development. Innovation and Expansion Kyowa Kirin and Kura Oncology Collaborate to Create Ziftomenib for Acute Leukemias In November 2024, in order to develop and market ziftomenib, Kura's selective oral menin inhibitor, which is being researched for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies, Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. announced they have formed a global strategic partnership. Kura will get USD 330 million up front as part of the deal, and it anticipates receiving up to USD 420 million in near-term milestone payments, including one when ziftomenib is introduced in the monotherapy relapsed/refractory (R/R) context. Merck Launched Phase III Trials for Novel Treatments for Blood Disorders and Cancer In January 2024, With the start of pivotal Phase III studies for four new candidates for solid tumors and hematologic malignancies, Merck's strong oncology and hematology portfolio is progressing. Essential thrombocythemia (ET), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), non-small cell lung cancer (NSCLC), some patients with endometrial carcinoma who have already received treatment, and metastatic castration-resistant prostate cancer (mCRPC) are among the conditions for which the company announced active enrollment for investigational medications. The firm is committed to ongoing research to broaden our portfolio of oncology treatments in order to continue addressing unmet needs in cancer care. The company has a rich history of transforming groundbreaking science into medicines that save and enhance lives worldwide. Inventive Sparks, Expanding Markets The key players operating the hematologic malignancies market includes, Johnson & Johnson Services Inc., Pfizer Inc., Novartis AG, AbbVie Inc., GlaxoSmithKline PLC., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Inc., Celgene Corporation, F. Hoffman-La Roche Ltd., Takeda Pharmaceutical Company Limited., and others. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS

ADCs Set for Growth Amid Regulatory Evolutions and Technological Advances
ADCs Set for Growth Amid Regulatory Evolutions and Technological Advances

Yahoo

time16 hours ago

  • Yahoo

ADCs Set for Growth Amid Regulatory Evolutions and Technological Advances

The Antibody Drug Conjugates Market presents opportunities in developing novel ADC platforms, expanding into new cancer types, and leveraging biomarker-driven patient selection. Growth is driven by increasing demand for targeted therapies, technological advancements, and investment in R&D despite competition and regulatory challenges. Antibody Drug Conjugates Market Dublin, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates: Market Share, and Growth Analysis by Product Type (Monoclonal Antibodies, Small Molecule Drugs), Application, End User, Technology" report has been added to Antibody Drug Conjugates Market size is valued at USD 11.1 billion in 2025 and is projected to reach USD 42.2 billion by 2033, registering a compound annual growth rate (CAGR) of 18.2% over the forecast period. The Antibody Drug Conjugates (ADCs) Market focuses on the development and commercialization of targeted cancer therapies. ADCs combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, delivering the drug directly to cancer cells while minimizing damage to healthy tissues. The market is driven by the increasing demand for targeted cancer therapies with improved efficacy and safety profiles. The market encompasses various ADC platforms, including linkers, payloads, and conjugation market is segmented based on target antigen, payload, linker, and application. The major target antigens include HER2, CD30, and CD33. The market caters to a diverse range of cancer types, including breast cancer, lymphoma, and leukemia. The market is characterized by intense competition among pharmaceutical and biotechnology companies, with a focus on developing novel ADC platforms and expanding the therapeutic applications of Antibody Drug Conjugates Market is subject to stringent regulatory requirements and evolving guidelines regarding cancer therapies. The market is also influenced by the increasing complexity of cancer biology and the need for highly specific and potent ADCs. The market is expected to continue its growth trajectory, driven by the increasing demand for targeted cancer therapies and the development of innovative ADC Insights: Antibody Drug Conjugates Market Development of novel ADC platforms with improved stability and efficacy. Expansion of ADC applications to solid tumors and other cancer types. Increasing use of biomarker-driven patient selection for ADC therapy. Growing interest in combination therapies involving ADCs and other cancer treatments. Rising adoption of next-generation sequencing and other technologies to optimize ADC development. Increasing prevalence of cancer and the need for effective treatments. Growing demand for targeted cancer therapies with improved safety profiles. Technological advancements in ADC development and conjugation technologies. Rising investment in research and development by pharmaceutical and biotechnology companies. Increasing availability of funding and partnerships for ADC development projects. High cost of ADC development and manufacturing. Complexity of ADC design and optimization. Challenges in delivering the payload to cancer cells and minimizing off-target effects. Evolving regulatory requirements and intellectual property considerations. Competition from alternative cancer therapies, such as immunotherapy and cell therapy What's Included in the Report? Global Antibody Drug Conjugates market size and growth projections, 2024-2034 North America Antibody Drug Conjugates market size and growth forecasts, 2024-2034 (United States, Canada, Mexico) Europe market size and growth forecasts, 2024-2034 (Germany, France, United Kingdom, Italy, Spain) Asia-Pacific Antibody Drug Conjugates market size and growth forecasts, 2024-2034 (China, India, Japan, South Korea, Australia) Middle East Africa Antibody Drug Conjugates market size and growth estimate, 2024-2034 (Middle East, Africa) South and Central America Antibody Drug Conjugates market size and growth outlook, 2024-2034 (Brazil, Argentina, Chile) Antibody Drug Conjugates market size, share and CAGR of key products, applications, and other verticals, 2024-2034 Short- and long-term Antibody Drug Conjugates market trends, drivers, challenges, and opportunities Antibody Drug Conjugates market insights, Porter's Five Forces analysis Profiles of 5 leading companies in the industry - overview, key strategies, financials, product portfolio and SWOT analysis Latest market news and developments Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2033 Estimated Market Value (USD) in 2025 $11.1 Billion Forecasted Market Value (USD) by 2033 $42.2 Billion Compound Annual Growth Rate 18.2% Regions Covered Global Antibody Drug Conjugates Market Segmentation By Product Type: Monoclonal Antibodies Small Molecule Drugs By Application: Oncology Autoimmune Diseases Infectious Diseases By End User: Hospitals Specialty Clinics Research Institutes By Technology: Chemical Linkers Bioconjugation Techniques By Distribution Channel: Direct Sales Distributors By Geography: North America (USA, Canada, Mexico) Europe (Germany, UK, France, Spain, Italy, Rest of Europe) Asia-Pacific (China, India, Japan, Australia, Vietnam, Rest of APAC) The Middle East and Africa (Middle East, Africa) South and Central America (Brazil, Argentina, Rest of SCA) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Antibody Drug Conjugates Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store